Breakthrough ICE3 Trial Shows Promising Cryoablation Results
Groundbreaking Results from IceCure's ICE3 Trial
IceCure Medical Ltd. has shared exciting news regarding its ProSense® cryoablation technology, showcasing the success of its ICE3 trial as published in the Annals of Surgical Oncology. This peer-reviewed publication highlights a remarkable 96.3% recurrence-free rate among women treated for early-stage, low-risk breast cancer.
Positive Outcomes for Patients with Early-Stage Breast Cancer
The findings presented in the article are particularly timely, as IceCure is preparing for an upcoming FDA Advisory Panel meeting to seek marketing authorization for ProSense® in treating low-risk breast cancer. A significant portion of the trial included 194 patients who successfully underwent cryoablation treatment. This innovative procedure showed fantastic satisfaction levels: 100% of both patients and treating physicians reported being pleased with the cosmetic outcomes.
Efficacy and Safety of Cryoablation Therapy
Dr. Richard E. Fine, the lead author of the study, expressed confidence in the safety and reliability of cryoablation with ProSense®. At the 5-year mark, the ipsilateral breast tumor recurrence (IBTR) rate was only 4.3%, with breast cancer survival rates reaching 96.7%. Furthermore, among the subset of patients receiving both cryoablation and endocrine therapy, the recurrence-free rate was an impressive 96.3%.
Advantages of ProSense® Cryoablation
Unlike traditional surgical methods such as lumpectomy, which necessitate full anesthesia and extensive recovery, ProSense® offers a less invasive, quicker procedure carried out under local anesthesia. Patients are likely to experience minimal pain and scarring, leading to a faster recovery time. These benefits position ProSense® as a viable option for women seeking alternatives to conventional surgery.
Study Highlights and Results
- All 194 patients involved in the trial met eligibility criteria and received successful cryoablation treatments.
- The trial recorded a mean age of participants at 74.9 years, with tumor sizes averaging 7.4 mm transverse and 8.1 mm sagittal.
- No serious device-related adverse events occurred during the trial.
- A significant improvement in patients' quality of life was observed, with p-values indicating noteworthy progress.
- Overall, 100% satisfaction regarding cosmetic results was recorded among both patients and physicians.
About IceCure Medical
IceCure Medical, trading on Nasdaq under the ticker (NASDAQ: ICCM), specializes in innovative liquid-nitrogen-based cryoablation systems designed to treat both benign and malignant tumors. Their technology offers a minimally invasive alternative to surgical interventions, widely utilized in treating various cancer types including breast, kidney, bone, and lung cancers.
Frequently Asked Questions
What is ProSense® Cryoablation?
ProSense® Cryoablation is a minimally invasive technique that uses extreme cold to destroy cancerous tumors. It is an alternative to traditional surgical methods for treating early-stage breast cancer.
What were the outcomes of the ICE3 trial?
The ICE3 trial demonstrated a 96.3% recurrence-free rate and showed high satisfaction among patients and physicians regarding the cosmetic outcomes.
How does cryoablation compare to lumpectomy?
Unlike lumpectomy, which requires full anesthesia and longer recovery, cryoablation offers a quicker, safer procedure with less pain and scarring.
What is the next step for IceCure Medical?
IceCure Medical is preparing for an FDA Advisory Panel meeting to discuss marketing authorization for ProSense® in the treatment of low-risk breast cancer.
Who is Dr. Richard E. Fine?
Dr. Richard E. Fine is a lead investigator in the ICE3 trial and has been recognized for his impactful work in the field of breast surgery, receiving awards for his contributions.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Benitec BioPharma's Promising Future in OPMD Treatment
- Alumis Inc.'s ESK-001 Shows Promise for Psoriasis Treatment
- LEO Pharma Shows Positive Tralokinumab Results for AD Relief
- CluePoints Unveils Innovative MSR Tool for Clinical Trials
- Exploring Rivian Automotive's Promising Future in EV Market
- Intelligent Bio Solutions Advances with Promising Test Results
- Core PCE Price Index Shows Minor Decline, Impact on Economy
- Lexicon to Showcase Critical Trial for HCM Treatment at Congress
- Breakthrough Study Shows BioProtect Balloon Spacer's Efficacy
- Groundbreaking Combination Therapy Achieves Remarkable Results
Recent Articles
- Mercedes-Benz and Hydro Collaborate for Sustainable Growth
- Aligos Therapeutics Welcomes New Chief Medical Officer Dr. Achneck
- TriLink BioTechnologies and Alphazyme Launch Innovative RNA Solution
- Lipella Pharmaceuticals Showcases Promising Trial Results for OLP
- Understanding New Shopping Trends for the 2024 Holiday Season
- Comfort Keepers Earns Top Ranking for Senior Home Care Services
- Capricor Therapeutics' BLA Submission Plans Bring New Hope
- CyberArk Marks a Decade of Growth and Innovation Since IPO
- Expanding Edge Data Center Market Reaches USD 27.22 Billion Potential
- Informatica Celebrates Two Decades of Innovation in Data Management
- Analyst Insights: DA Davidson Adjusts Braze Inc Price Target
- Exploring the Growth of the Epigenetics Market by 2031
- WM Achieves Positive Results in Stericycle Notes Exchange Offer
- Apheresis Equipment Market Growth Forecasted at 9% CAGR
- Miniso Faces Uncertainty After Stake Acquisition in Yonghui Superstores
- Epineuron Achieves Health Canada Approval for Nerve Therapy System
- Redburn Downgrades BP and Exxon: Oil Price Forecasts Lowered
- Quality Management Software Market Forecast: Significant Growth Ahead
- Spineology Inc. Unveils New Brand Identity Amid Innovations
- UBS Downgrades Luxury Giants Swatch Group and Moncler Amid Soft Demand
- HouseAmp and BOSSCAT™ Collaboration Enhances Home Selling Solutions
- Maxar Intelligence’s Expansion Marks a New Era of Geospatial Solutions
- CrowdStrike Executive Acknowledges Software Update Failure
- Spine BioPharma Completes Enrollment for Critical Clinical Trial
- CoinW's Thrilling Show at TOKEN2049: Partners, Parties, and More
- Meta Platforms Empowers AI Chatbot with Celebrity Voices
- SURE and SageSure Launch Comprehensive Insurance Solution
- Innovations in Photonics: Syntec Optics Leads the Way in Technology
- Unlocking Holiday Gifting with the Giftcards.com Gift Card
- Standard Lithium's Bold Steps Towards Sustainable Lithium Production
- Innovative Training Solutions for Suppliers by LRN Corporation
- NetApp's Vision for AI Innovation in Data Management
- NV5 Secures Major Geospatial Contract Worth Up to $290 Million
- Canadian North Resources Enhances Community Connections for Ferguson Lake
- Composition Capital: Pioneering Growth in Technology Investments
- Matthews International Sets Senior Note Pricing for Future Growth
- Transforming Dealer Profitability with EFG Wealth Builder
- Micruity Strengthens Leadership with Mike Westhoven's Appointment
- Arcutis Advances ZORYVE Submission for Psoriasis Treatment
- Newlab Welcomes Carl Wolf as CCOO for Global Expansion Efforts
- Casella Waste Systems: Leading the Charge in Sustainable Practices
- WOW Carwash Welcomes Heath Pomerantz as New CEO
- Enphase Energy Introduces Innovative IQ Battery for India
- RuralWorks Partners' Investment in Glavel for Green Solutions
- A-Mark Precious Metals Confirms Ongoing Dividend for Investors
- Analyzing Job Market Trends and Economic Implications
- Foundever's Innovative AI Recognition by Frost & Sullivan
- Strategic Partnership Enhances Propel Engineering's Services
- Key Developments Following Savaria Corporation's Share Sale
- Exploring Democracy and AI: Insights from Stanford's Lab